Trial reportThe New England journal of medicine2026
Prime Editing for p47
Abstract readClinical Trial, Phase IClinical Trial, Phase IIMulticenter Study
In one paragraph
Trial report in The New England journal of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Prime Editing: An Overview.Methods in molecular biology (Clifton, N.J.) · 2027Review
- Gene therapy for hereditary hematological disorders: From clinical breakthroughs to future horizons.Molecular therapy. Nucleic acids · 2026Review
- Human inborn errors of the phagocyte respiratory burst: Chronic granulomatous disease and beyond.Journal of human immunity · 2026Article
- Beyond Precision: A Multidimensional Framework for Selecting Genetic Medicine Platforms.Cells · 2026Review
- Mechanistic machine learning for prediction of prime editing outcomes.Nature biotechnology · 2026Article
- CRISPR application in hematological disorders: from bench to bedside.Blood advances · 2026Review
- Fungal Infections in Disorders of Inborn Errors of Immunity.Clinical reviews in allergy & immunology · 2026Review
- Red lines and green lights: Gene therapy for inherited erythroid disorders beyond the haemoglobinopathies.British journal of haematology · 2026Review
- CD117 epitope-shielded hematopoietic stem cell transplantation with toxin-free conditioning and in vivo selection ameliorates a β-thalassemia model.bioRxiv : the preprint server for biology · 2026Article
- Engineered Neutrophils in Translational Medicine: Gene Editing, Nanotechnology, and AI-Driven Clinical Breakthroughs.Advanced healthcare materials · 2026Review
- Adapting prime editing with split prime editors in Escherichia coli and its application to Staphylococcus aureus genome editing.Applied microbiology and biotechnology · 2026Article
- A primer on prime: A prime editing update from advances to first-in-human trial.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Review
- Prime editing updates: technological evolution, methodological expansion, and delivery strategies for in vivo applications.BMB reports · 2026Review
- Review
- How I Treat: Chronic granulomatous disease.Journal of human immunity · 2026Review
- Clinical Trial Landscape of Gene-Edited Autologous Hematopoietic Stem Cells for Hemoglobinopathies and Immunodeficiencies.International journal of molecular sciences · 2026Review
- A Comprehensive Review of IL-10 and IL-10 Receptor Deficiencies: From Basic Science to Clinical Bedside.Clinical reviews in allergy & immunology · 2026Review
- Keep up the momentum for gene therapies.Nature medicine · 2026Article
- The New Wave of Gene and Cell Therapies Across Diseases.Journal of clinical medicine · 2026Review
- Perspectives on chronic granulomatous disease: results of a clinician survey.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors.
Jennifer L GoriPrime Medicine, Cambridge, MA.
Elie HaddadDepartment of Pediatrics, CHU Sainte-Justine Azrieli Research Center, Université de Montréal, Montreal.ORCID 0000-0003-2446-6879
Haydar FrangoulSarah Cannon Research Institute, Children's Hospital at TriStar Centennial, Nashville.ORCID 0000-0002-0590-2826
Donald B KohnDepartment of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles.
Emma C MorrisNational Institute for Health and Care Research, University College London Hospitals Biomedical Research Centre, London.
Bradley N MartinPrime Medicine, Cambridge, MA.
Briana A DearyPrime Medicine, Cambridge, MA.
McKinley NickersonPrime Medicine, Cambridge, MA.
Rebecca L ScholzPrime Medicine, Cambridge, MA.
Isabel FernandezDepartment of Pediatrics, CHU Sainte-Justine Azrieli Research Center, Université de Montréal, Montreal.
Karine LeveilleDepartment of Pediatrics, CHU Sainte-Justine Azrieli Research Center, Université de Montréal, Montreal.
Suk See De RavinLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
Elizabeth M KangLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
Marie PierzynskiLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
Tyra EstwickLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
Patricia LittelLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
Douglas B KuhnsLeidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD.
Debra A Long PrielLeidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD.
Pierre TeiraDepartment of Pediatrics, CHU Sainte-Justine Azrieli Research Center, Université de Montréal, Montreal.
Stuart TurveyDepartment of Pediatrics, British Columbia Children's Hospital, University of British Columbia, Vancouver, Canada.
Jordyn ArnoldDepartment of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles.
Misty D EvansSarah Cannon Research Institute, Children's Hospital at TriStar Centennial, Nashville.
Meghann McManusSarah Cannon Research Institute, Children's Hospital at TriStar Centennial, Nashville.
Ben CarpenterDepartment of Hematology, University College London Hospitals NHS Foundation Trust, London.
David P WatermanPrime Medicine, Cambridge, MA.
Andrew V AnzalonePrime Medicine, Cambridge, MA.
Alexandria PetrusichPrime Medicine, Cambridge, MA.
Christa E OsunaPrime Medicine, Cambridge, MA.
Tiernan T O'MalleyPrime Medicine, Cambridge, MA.
Jacob Stewart-OrnsteinPrime Medicine, Cambridge, MA.
Jack M HeathPrime Medicine, Cambridge, MA.
Barrett J NehillaPrime Medicine, Cambridge, MA.
Mohammed AsmalPrime Medicine, Cambridge, MA.
Harry L MalechLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
Funding
Gene Therapy Basic Research to Treat Inherited Primary Immune DeficienciesZIAAI000644 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI MALECH, HARRY L · 2009 to 2025
$12.1MDevelopment and Clinical Application of Gene and Cell therapies for Patients with Immune DeficienciesZIAAI000645 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DE RAVIN, SUK SEE · 2009 to 2025
$10.1MPERIPHERAL BLOOD PROGENITORS-TARGET FOR GENE TRANSFERZ01AI000644 · NIAID · NIAID EXTRAMURAL ACTIVITIES · PI MALECH, HARRY L · 1992 to 2008
$4.3MGENE THERAPY FOR IMMUNE DEFICIENCIESZ01AI000645 · NIAID · NIAID EXTRAMURAL ACTIVITIES · PI DE RAVIN, SUK · 1992 to 2008
$873kCCR NIH HHS HHSN261200800001CIntramural NIH HHS Z01 AI000644Intramural NIH HHS Z01 AI000645Intramural NIH HHS ZIA AI000644Intramural NIH HHS ZIA AI000645NCI NIH HHS HHSN261200800001ENIH HHS HHSN261200800001E
Abstract
Chronic granulomatous disease (CGD) is a severe monogenic immunodeficiency caused by damaging variants in genes required for microbicidal NADPH oxidase activity. Autosomal recessive p47
Indexed as
Gene EditingGenetic TherapyGranulomatous Disease, ChronicHematopoietic Stem Cell TransplantationNADPH OxidasesAdolescentBusulfanExonsFollow-Up StudiesHumansMaleMiddle AgedNeutrophilsPseudogenesSequence DeletionTransplantation, AutologousBusulfanNADPH Oxidasesneutrophil cytosolic factor 1
Identifiers
What Socratic holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.